Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4D Molecular TherapeuticsFDMT +1.91%55 Equity-to-Asset is 0.88 as of Mar. 2026, which is 2% below its 10-year median of 0.90. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $124.16 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, 4D Molecular Therapeutics ranks better than 79.39% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
4D Molecular Therapeutics Equity-to-Asset Related Terms
4D Molecular Therapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FDMT vs CTNM, PRME, VSTM: Equity-to-Asset Comparison
For the Biotechnology subindustry, 4D Molecular Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
4D Molecular Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics (FDMT) has a Equity-to-Asset of 0.88 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4D Molecular Therapeutics and its competitors. This is near median its historical median of 0.90. According to the industry distribution chart, 4D Molecular Therapeutics ranks #292 out of 1417 companies in the Biotechnology industry, placing it in the top 20.6%.
Is 4D Molecular Therapeutics' Equity-to-Asset too high?
4D Molecular Therapeutics' current Equity-to-Asset of 0.88 is near median its 10-year median of 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. 4D Molecular Therapeutics' value of 0.88 is 29.4% above this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #292 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Equity-to-Asset compare to CTNM and PRME?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #292 out of 1417 companies for Equity-to-Asset. This places 4D Molecular Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. 4D Molecular Therapeutics' value of 0.88 is 29.4% above this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 0.68, 4D Molecular Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current Equity-to-Asset of 0.88 is 29.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4D Molecular Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $124.16, compared to a current price of $10.47 — trading 91.6% below its estimated fair value. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.90 and 29.4% above the Biotechnology industry median of 0.68. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Equity-to-Asset is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $10.47 is trading 91.6% below its estimated GF Value™ of $124.16.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
Equity-to-Asset: 0.88 (near median its 10-year median of 0.90)
GF Value™: $124.16 vs. price of $10.47 (91.6% below fair value)
Industry Position: 29.4% above the Biotechnology median (#292 of 1417)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score
Get the complete analysis for FDMT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
